MwanzoATYR • NASDAQ
add
aTyr Pharma Inc
$ 3.35
Baada ya Saa za Kazi:(1.19%)+0.040
$ 3.39
Imefungwa: 25 Apr, 18:57:32 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 3.45
Bei za siku
$ 3.29 - $ 3.47
Bei za mwaka
$ 1.42 - $ 4.66
Thamani ya kampuni katika soko
297.68M USD
Wastani wa hisa zilizouzwa
1.42M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 0.00 | — |
Matumizi ya uendeshaji wa biashara | 3.59M | 12.11% |
Mapato halisi | -14.97M | -1.40% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.18 | 28.00% |
EBITDA | -15.64M | 0.88% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 72.12M | -26.53% |
Jumla ya mali | 96.83M | -19.75% |
Jumla ya dhima | 27.00M | -10.55% |
Jumla ya hisa | 69.83M | — |
hisa zilizosalia | 88.86M | — |
Uwiano wa bei na thamani | 4.16 | — |
Faida inayotokana na mali | -41.97% | — |
Faida inayotokana mtaji | -48.88% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -14.97M | -1.40% |
Pesa kutokana na shughuli | -13.13M | -18.71% |
Pesa kutokana na uwekezaji | -6.08M | -134.15% |
Pesa kutokana na ufadhili | 18.84M | 212.21% |
Mabadiliko halisi ya pesa taslimu | elfu -378.00 | -102.96% |
Mtiririko huru wa pesa | -7.83M | -52.29% |
Kuhusu
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Ilianzishwa
1 Jan 2005
Tovuti
Wafanyakazi
61
